18 June 2015
Venue: Willoughby Lecture Theatre, John Vane Science Centre, Charterhouse Square, EC1M 6BQ
The increasing understanding of the biology of breast cancer has opened the way to targeted, personalised medicine by utilising existing treatments more efficiently, modulating resistance and developing new treatment strategies. Prof Schmid will consider the emerging options and associated challenges, considering the impact of new targeted therapies, cancer immunotherapy, and the change of thinking about how research is conducted to deliver personalised treatment.
Professor Peter Schmid was appointed as Chair in Cancer Medicine at Barts Cancer Institute, Queen Mary University London, in 2013. He is Lead of the Centre of Experimental Cancer Medicine at Barts Cancer Institute and is lead of clinical research at Barts. Professor Schmid also leads the academic breast and lung cancer programmes and the cancer immune therapy group at Barts Cancer Institute.
Professor Schmid trained in medicine in Munich and Aberdeen. He was awarded scholarships by the 'Studienstiftung des deutschen Volkes', the 'Hanns-Seidel-Foundation', and the 'Deutscher Akademischer Austauschdienst'. Professor Schmid completed a MD in clinical chemistry at the Technical University Munich in 1998 and a PhD in oncology at the Charité University in Berlin in 2005. Professor Schmid completed his clinical training in internal medicine, haematology and oncology at the University Hospital Charité in Berlin. From 2005-2010, Professor Schmid was a Senior Clinical Lecturer and Director of the Hammersmith Early Clinical Trials Unit at Imperial College London. In 2010, he was appointed as Foundation Chair in Cancer Medicine at the University of Sussex where he worked until his move to Barts.
Professor Schmid’s research interests lie in cancer immune therapy, therapeutic resistance and stratified cancer medicine utilising novel biomarkers and innovative, biomarker-driven clinical trial strategies. Professor Schmid has successfully led >20 national/international academic clinical studies and he leads a substantial translational research programme focusing on circulating biomarkers in blood samples.
A reception will follow the lecture.